Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

By A. Gordon, J. Fleagle, D. Guthrie, D. Parkin, M. Gore, Á. Lacave. Journal of Clinical Oncology, 2001

1,216 citations recorded by the source corpus.

Subfields: Biomaterials, Reproductive Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/ffd5da3299165ae907930fc35cf5f29fcfc7ed63

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. F. Danhier
2. Daniel G. Anderson
3. V. Préat
4. Phatsapong Yingchoncharoen
5. P. Couvreur
6. Robert Langer
7. D. Richardson
8. D. Kalinowski

In Reproductive Medicine

1. A. D’Andrea
2. D. K. Armstrong
3. D. Jelovac
4. Jonathan A. Ledermann
5. Raphael Ceccaldi
6. C. Sessa
7. D. Querleu

In Surgery

1. Robert Langer
2. D. K. Armstrong
3. D. Jelovac
4. V. Mohanraj
5. Y. Chen

Citations in the corpus

• Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. (2012, background): “Only in certain specific cases, such as in patients suffering from Kaposi sarcoma and from cisplatin-responsive ovarian carcinoma, clear-cut improvements in response rates and overall survival times were observed, whereas in all other cases, such as in metastatic breast cancer and in mutlple myeloma”
• Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come (2016, methodology): “Recently, one study demonstrated that Lipodox did not show equivalent efficacy as Doxil in patients for the treatment of ovarian cancer (Smith et al., 2015).”
• Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. (2004, background): “The results of these trials indicated that a dosage of 50 mg/m(2) every 4 weeks is clinically active and well tolerated [6, 7].”
• ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (2019, background): “For example, in a study [296] comparing PLD and topotecan, platinum-resistant patients received on average 4.”
• Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. (2013, background): “Although a couple of positive trials with nanomedicines have been reported, including Doxil for metastatic ovarian cancer [69] and Abraxane for metastatic breast cancer [70], the benefit of nanomedicine in clinical patients has not been consistent.”